{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T21:52:17Z","timestamp":1788817937760,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the 2022 University-level Research Projects of Southwest Medical University","award":["No.2022QN006"],"award-info":[{"award-number":["No.2022QN006"]}]},{"name":"the Doctoral Research Initiation Fund of Affiliated Hospital of Southwest Medical University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-15477-9","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T17:43:18Z","timestamp":1755106998000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cost-effectiveness of polatuzumab vedotin plus chemoimmunotherapy for untreated diffuse large B-cell lymphoma in China"],"prefix":"10.1038","volume":"15","author":[{"given":"Mengya","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinhui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changjing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longyang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,13]]},"reference":[{"key":"15477_CR1","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/ajh.24086","volume":"90","author":"M Al-Hamadani","year":"2015","unstructured":"Al-Hamadani, M. et al. Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National cancer data base from 1998 to 2011. Am. J. Hematol. 90, 790\u2013795 (2015).","journal-title":"Am. J. Hematol."},{"key":"15477_CR2","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"15477_CR3","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","volume":"396","author":"GBD Diseases","year":"2020","unstructured":"Diseases, G. B. D. & Injuries, C. Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the global burden of disease study 2019. Lancet 396, 1204\u20131222 (2020).","journal-title":"Lancet"},{"key":"15477_CR4","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.18632\/aging.204006","volume":"14","author":"W Liu","year":"2022","unstructured":"Liu, W. et al. Burden of lymphoma in china, 1990\u20132019: an analysis of the global burden of diseases, injuries, and risk factors study 2019. Aging (Albany NY). 14, 3175\u20133190 (2022).","journal-title":"Aging (Albany NY)"},{"key":"15477_CR5","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","volume":"116","author":"B Coiffier","year":"2010","unstructured":"Coiffier, B. et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the groupe d\u2019etudes des lymphomes de l\u2019adulte. Blood 116, 2040\u20132045 (2010).","journal-title":"Blood"},{"key":"15477_CR6","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","volume":"109","author":"LH Sehn","year":"2007","unstructured":"Sehn, L. H. et al. The revised international prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109, 1857\u20131861 (2007).","journal-title":"Blood"},{"key":"15477_CR7","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1200\/JCO.2017.73.2784","volume":"35","author":"JP Leonard","year":"2017","unstructured":"Leonard, J. P. et al. Randomized phase II study of R-CHOP with or without bortezomib in previously untreated patients with Non-Germinal center B-Cell-Like diffuse large B-Cell lymphoma. J. Clin. Oncol. 35, 3538\u20133546 (2017).","journal-title":"J. Clin. Oncol."},{"key":"15477_CR8","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1200\/JCO.18.02403","volume":"37","author":"A Younes","year":"2019","unstructured":"Younes, A. et al. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in Non-Germinal center B-Cell diffuse large B-Cell lymphoma. J. Clin. Oncol. 37, 1285\u20131295 (2019).","journal-title":"J. Clin. Oncol."},{"key":"15477_CR9","doi-asserted-by":"crossref","unstructured":"Vitolo, U. et al. ROBUST: first report of phase III randomized study of lenalidomide\/R-CHOP (R2\u2010CHOP) vs placebo\/R\u2010CHOP in previously untreated ABC\u2010type diffuse large B\u2010cell lymphoma. Hematol. Oncol. 37, 36-37 (2019).","DOI":"10.1002\/hon.5_2629"},{"key":"15477_CR10","unstructured":"US Food and Drug Administration. POLIVYVR US Prescribing Information. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761121s000lbl.pdf (Accessed 14 December 2023)."},{"key":"15477_CR11","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/S1470-2045(15)70128-2","volume":"16","author":"MC Palanca-Wessels","year":"2015","unstructured":"Palanca-Wessels, M. C. et al. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab Vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Lancet Oncol. 16, 704\u2013715 (2015).","journal-title":"Lancet Oncol."},{"key":"15477_CR12","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1200\/JCO.19.00172","volume":"38","author":"LH Sehn","year":"2020","unstructured":"Sehn, L. H. et al. Polatuzumab Vedotin in relapsed or refractory diffuse large B-Cell lymphoma. J. Clin. Oncol. 38, 155\u2013165 (2020).","journal-title":"J. Clin. Oncol."},{"key":"15477_CR13","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1111\/cas.14937","volume":"112","author":"Y Terui","year":"2021","unstructured":"Terui, Y. et al. A phase 2 study of polatuzumab vedotin\u2009+\u2009bendamustine\u2009+\u2009rituximab in relapsed\/refractory diffuse large B-cell lymphoma. Cancer Sci. 112, 2845\u20132854 (2021).","journal-title":"Cancer Sci."},{"key":"15477_CR14","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/S1470-2045(19)30091-9","volume":"20","author":"H Tilly","year":"2019","unstructured":"Tilly, H. et al. Polatuzumab Vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study. Lancet Oncol. 20, 998\u20131010 (2019).","journal-title":"Lancet Oncol."},{"key":"15477_CR15","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","volume":"386","author":"H Tilly","year":"2022","unstructured":"Tilly, H. et al. Polatuzumab Vedotin in previously untreated diffuse large B-Cell lymphoma. N Engl. J. Med. 386, 351\u2013363 (2022).","journal-title":"N Engl. J. Med."},{"key":"15477_CR16","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","volume":"21","author":"N Liu","year":"2021","unstructured":"Liu, N., Zhou, Y. & Lee, J. J. IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves. BMC Med. Res. Methodol. 21, 111 (2021).","journal-title":"BMC Med. Res. Methodol."},{"key":"15477_CR17","unstructured":"China Foreign Exchange Trade System & National Interbank Funding Center. March (2024). Available at: https:\/\/www.chinamoney.com.cn\/chinese\/bkccpr\/ (Accessed 2."},{"key":"15477_CR18","unstructured":"Liu, G. E. Guidelines for pharmacoeconomic evaluation in China Beijing: China Market Publishing House (2020). (2020)."},{"key":"15477_CR19","unstructured":"Yao, Z. H. The big data service platform for china\u2019s health industry: information query of drug bid winning (2024). Available at: https:\/\/db.yaozh.com (Accessed 15 March 2024)."},{"key":"15477_CR20","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1007\/s12325-022-02101-9","volume":"39","author":"Y Zhu","year":"2022","unstructured":"Zhu, Y., Liu, K., Ding, D., Zhou, Y. & Peng, L. Pembrolizumab plus chemotherapy as First-Line treatment for advanced esophageal cancer: A Cost-Effectiveness analysis. Adv. Ther. 39, 2614\u20132629 (2022).","journal-title":"Adv. Ther."},{"key":"15477_CR21","first-page":"6113","volume":"30","author":"N Li","year":"2022","unstructured":"Li, N. et al. Cost-effectiveness analysis of Axicabtagene Ciloleucel vs. salvage chemotherapy for relapsed or refractory adult diffuse large B-cell lymphoma in China. Support. Care Cancer. 30, 6113\u20136121 (2022).","journal-title":"Support. Care Cancer"},{"key":"15477_CR22","doi-asserted-by":"publisher","first-page":"e230073","DOI":"10.57264\/cer-2023-0073","volume":"12","author":"J Ma","year":"2023","unstructured":"Ma, J. et al. Cost-effectiveness of obinutuzumab plus Bendamustine in Chinese patients with relapse and refractory follicular lymphoma. J. Comp. Eff. Res. 12, e230073 (2023).","journal-title":"J. Comp. Eff. Res."},{"key":"15477_CR23","unstructured":"National Institute for Health and Care Excellence. Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma. Available at: https:\/\/www.nice.org.uk\/guidance\/ta874 (Accessed 15 December 2023)."},{"key":"15477_CR24","doi-asserted-by":"crossref","unstructured":"24 et al. US cost-effectiveness analysis of polatuzumab Vedotin in previously untreated diffuse large B-cell lymphoma. J. Med. Econ. 26, 1134\u20131144 (2023).","DOI":"10.1080\/13696998.2023.2254640"},{"key":"15477_CR25","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1080\/14737167.2023.2196408","volume":"23","author":"T Munir","year":"2023","unstructured":"Munir, T. et al. Cost-effectiveness of acalabrutinib regimens in treatment-naive chronic lymphocytic leukemia in the united States. Expert Rev. Pharmacoecon Outcomes Res. 23, 579\u2013589 (2023).","journal-title":"Expert Rev. Pharmacoecon Outcomes Res."},{"key":"15477_CR26","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.breast.2022.10.010","volume":"66","author":"Y Zhu","year":"2022","unstructured":"Zhu, Y., Liu, K., Wang, M., Wang, K. & Zhu, H. Trastuzumab Deruxtecan versus trastuzumab emtansine for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: A cost-effectiveness analysis. Breast 66, 191\u2013198 (2022).","journal-title":"Breast"},{"key":"15477_CR27","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/1477-7525-8-50","volume":"8","author":"KM Beusterien","year":"2010","unstructured":"Beusterien, K. M. et al. Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study. Health Qual. Life Outcomes. 8, 50 (2010).","journal-title":"Health Qual. Life Outcomes"},{"key":"15477_CR28","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1080\/13696998.2023.2254162","volume":"26","author":"T Mizuoka","year":"2023","unstructured":"Mizuoka, T. et al. Cost-effectiveness of combination therapy of polatuzumab Vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisolone for previously untreated diffuse large B-cell lymphoma in Japan. J. Med. Econ. 26, 1122\u20131133 (2023).","journal-title":"J. Med. Econ."},{"key":"15477_CR29","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1182\/blood.2022017734","volume":"141","author":"Y Song","year":"2023","unstructured":"Song, Y. et al. Polatuzumab Vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial. Blood 141, 1971\u20131981 (2023).","journal-title":"Blood"},{"key":"15477_CR30","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1182\/blood-2013-09-524108","volume":"123","author":"Z Zhou","year":"2014","unstructured":"Zhou, Z. et al. An enhanced international prognostic index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 123, 837\u2013842 (2014).","journal-title":"Blood"},{"key":"15477_CR31","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1200\/JCO.2013.51.5866","volume":"32","author":"MJ Maurer","year":"2014","unstructured":"Maurer, M. J. et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J. Clin. Oncol. 32, 1066\u20131073 (2014).","journal-title":"J. Clin. Oncol."},{"key":"15477_CR32","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1200\/JCO.2016.70.0765","volume":"35","author":"LH Jakobsen","year":"2017","unstructured":"Jakobsen, L. H. et al. Minimal loss of lifetime for patients with diffuse large B-Cell lymphoma in remission and event free 24 months after treatment: A Danish Population-Based study. J. Clin. Oncol. 35, 778\u2013784 (2017).","journal-title":"J. Clin. Oncol."},{"key":"15477_CR33","unstructured":"Roche Company. Roche presents new and updated data for Polivy in previously untreated diffuse large B-cell lymphoma at ASH (2022). Available at: https:\/\/www.globenewswire.com\/news-release\/2022\/12\/12\/2571491\/0\/en\/Roche-presents-new-and-updated-data-for-Polivy-in-previously-untreated-diffuse-large-B-cell-lymphoma-at-ASH-2022.html (Accessed 28 November 2023)."},{"key":"15477_CR34","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","volume":"393","author":"S Horwitz","year":"2019","unstructured":"Horwitz, S. et al. Brentuximab Vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet 393, 229\u2013240 (2019).","journal-title":"Lancet"},{"key":"15477_CR35","doi-asserted-by":"crossref","unstructured":"Zhang, Y. et al. The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China. BMJ Glob Health 6, 1-11 (2021).","DOI":"10.1136\/bmjgh-2021-006196"},{"key":"15477_CR36","doi-asserted-by":"publisher","first-page":"469580231170729","DOI":"10.1177\/00469580231170729","volume":"60","author":"X Mingge","year":"2023","unstructured":"Mingge, X., Jingyu, W., Qi, L., Zhe, Z. & Qing, R. Promoting access to innovative anticancer medicines: A review of drug price and National reimbursement negotiation in China. Inquiry 60, 469580231170729 (2023).","journal-title":"Inquiry"},{"key":"15477_CR37","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1111\/bjh.18869","volume":"202","author":"S Kambhampati","year":"2023","unstructured":"Kambhampati, S. et al. Cost-effectiveness of polatuzumab Vedotin in combination with chemoimmunotherapy (pola-R-CHP) in previously untreated diffuse large B-cell lymphoma in Germany. Br. J. Haematol. 202, 771\u2013775 (2023).","journal-title":"Br. J. Haematol."},{"key":"15477_CR38","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1200\/JCO.22.00478","volume":"41","author":"A Vijenthira","year":"2023","unstructured":"Vijenthira, A., Kuruvilla, J., Crump, M., Jain, M. & Prica, A. Cost-Effectiveness analysis of frontline Polatuzumab-Rituximab, cyclophosphamide, doxorubicin, and prednisone and\/or Second-Line chimeric antigen receptor T-Cell therapy versus standard of care for treatment of patients with Intermediate- to High-Risk diffuse large B-Cell lymphoma. J. Clin. Oncol. 41, 1577\u20131589 (2023).","journal-title":"J. Clin. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15477-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15477-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15477-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T13:17:15Z","timestamp":1757423835000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15477-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,13]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["15477"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-15477-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,13]]},"assertion":[{"value":"6 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"No human participants or animals presented in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"29752"}}